MX338426B - Enzima de enfermedad del almacenamiento lisosomico. - Google Patents

Enzima de enfermedad del almacenamiento lisosomico.

Info

Publication number
MX338426B
MX338426B MX2012012356A MX2012012356A MX338426B MX 338426 B MX338426 B MX 338426B MX 2012012356 A MX2012012356 A MX 2012012356A MX 2012012356 A MX2012012356 A MX 2012012356A MX 338426 B MX338426 B MX 338426B
Authority
MX
Mexico
Prior art keywords
acid lipase
lysosomal acid
lysosomal storage
storage disease
human lysosomal
Prior art date
Application number
MX2012012356A
Other languages
English (en)
Other versions
MX2012012356A (es
Inventor
Anthony Quinn
Alex J Harvey
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of MX2012012356A publication Critical patent/MX2012012356A/es
Publication of MX338426B publication Critical patent/MX338426B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que comprende una lipasa ácida lisosomal recombinante humana aislada (rhLAL) en combinación con un portador, diluyente o excipiente farmacéuticamente estable, en donde dicho rhLAL comprende una o más estructura N-glicanos, en donde el rhLAL se encuentra glicosilada unida por N en Asn15, Asn80, Asn140, Asn252 y Asn300 de la SEQ ID NO: 2, y en donde la formulación farmacéutica es una solución acuosa que tiene un pH de entre 5.6 y 6.2 o un pH de 5.9+-0.2.
MX2012012356A 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico. MX338426B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34317710P 2010-04-23 2010-04-23
US39637610P 2010-05-26 2010-05-26
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme

Publications (2)

Publication Number Publication Date
MX2012012356A MX2012012356A (es) 2013-04-11
MX338426B true MX338426B (es) 2016-04-15

Family

ID=44834852

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004772A MX362430B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.
MX2012012356A MX338426B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016004772A MX362430B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.

Country Status (21)

Country Link
US (4) US20130209436A1 (es)
EP (3) EP3205351B1 (es)
JP (4) JP5925187B2 (es)
KR (1) KR101742346B1 (es)
CN (2) CN105214076B (es)
AU (1) AU2011242461B2 (es)
BR (1) BR112012027143B1 (es)
CA (2) CA2995446C (es)
DK (2) DK2561069T3 (es)
ES (2) ES2950358T3 (es)
FI (1) FI3205351T3 (es)
HK (2) HK1183059A1 (es)
HU (2) HUE033217T2 (es)
IL (2) IL222513A0 (es)
LT (1) LT3205351T (es)
MX (2) MX362430B (es)
PL (2) PL2561069T3 (es)
PT (2) PT3205351T (es)
RU (2) RU2015151189A (es)
SI (2) SI2561069T1 (es)
WO (1) WO2011133960A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
WO2008091311A1 (en) * 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
PL2561069T3 (pl) 2010-04-23 2017-08-31 Alexion Pharmaceuticals, Inc. Enzym lizosomalnej choroby spichrzeniowej
CN105457018A (zh) 2010-09-09 2016-04-06 辛那杰瓦生物制药股份有限公司 使用溶酶体酸性脂肪酶来治疗患者的溶酶体酸性脂肪酶缺乏
EP2675472A4 (en) * 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
MX2016013713A (es) * 2014-04-23 2017-05-03 Alexion Pharma Inc Procesamiento de clara de huevo.
WO2017218926A1 (en) 2016-06-17 2017-12-21 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
US11155794B2 (en) * 2016-08-23 2021-10-26 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
WO2018064303A1 (en) 2016-09-30 2018-04-05 Alexion Pharmaceuticals, Inc. Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
WO2019152343A1 (en) 2018-02-01 2019-08-08 Alexion Pharmaceuticals, Inc. Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal
JP2022538497A (ja) * 2019-07-02 2022-09-02 エム６ピー セラピューティクス （スイッツァランド） ゲーエムベーハー ライソゾーム蓄積症を処置するためのベクター組成物およびそれを使用する方法
CN114369620B (zh) * 2021-12-31 2024-05-24 广州博垚生物科技有限公司 一种可持续分泌lal的载体、脐带间充质干细胞及其构建方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996004001A1 (en) 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
EP0865499B1 (en) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Production of lysosomal enzymes in plant-based expression systems
DK2374876T3 (en) 1996-09-13 2016-05-30 Shire Human Genetic Therapies A process for the purification of alpha-galactosidase A
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
PT2020438T (pt) 1998-12-07 2018-07-13 Genzyme Corp Tratamento da doença de pompe
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002036754A2 (en) 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6387680B1 (en) * 2001-03-29 2002-05-14 Pe Corporation (Ny) Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20050181474A1 (en) 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor
EP1495328B1 (en) 2002-04-16 2014-06-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A marker for measuring liver cirrhosis
AU2003283976B2 (en) 2002-09-27 2009-12-10 Cold Spring Harbor Laboratory Cell-based RNA interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
BRPI0514409A (pt) 2004-08-19 2008-06-10 Biogen Idec Inc redobra de proteìnas da famìlia de fator de crescimento transformante beta
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US8124732B2 (en) 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
WO2007030375A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US7524626B2 (en) 2005-10-05 2009-04-28 Synageva Biopharma Corp. Rapid production of high titer virus
US20070092486A1 (en) 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
EP2037945A4 (en) 2006-05-24 2012-07-04 Myelin Repair Foundation Inc PERMEABILITY OF THE HEMATO-ENCEPHALIC BARRIER
WO2008091311A1 (en) 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
AU2008256644B2 (en) 2007-05-24 2014-07-03 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
CN101686996B (zh) 2007-05-31 2012-12-05 格莱肯生物科学公司 硫酸木聚糖在制备用于治疗或预防呼吸疾病的药物的新用途
CN101790385A (zh) 2007-07-12 2010-07-28 普罗森那技术公司 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子
EP2185187A1 (en) 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
KR101343485B1 (ko) * 2008-01-07 2013-12-20 시나게바 바이오파르마, 코포레이션 조류에서의 당화
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
CA2766614C (en) 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US8604057B2 (en) 2009-10-19 2013-12-10 Amicus Therapeutics, Inc. Compositions for preventing and/or treating lysosomal storage disorders
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US20150030582A1 (en) * 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
PL2561069T3 (pl) 2010-04-23 2017-08-31 Alexion Pharmaceuticals, Inc. Enzym lizosomalnej choroby spichrzeniowej
CN105457018A (zh) 2010-09-09 2016-04-06 辛那杰瓦生物制药股份有限公司 使用溶酶体酸性脂肪酶来治疗患者的溶酶体酸性脂肪酶缺乏
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
BR112013021494B1 (pt) 2011-02-22 2021-09-08 California Institute Of Technology Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
MX351565B (es) 2011-08-03 2017-10-19 Phoenix Tissue Repair Inc Colageno 7 y metodos relacionados.

Also Published As

Publication number Publication date
AU2011242461A1 (en) 2012-11-15
RU2741116C2 (ru) 2021-01-22
WO2011133960A3 (en) 2012-07-12
CN105214076A (zh) 2016-01-06
EP4241854A3 (en) 2023-11-08
JP5925187B2 (ja) 2016-05-25
HK1183059A1 (en) 2013-12-13
MX2012012356A (es) 2013-04-11
US20200063113A1 (en) 2020-02-27
DK3205351T3 (da) 2023-06-19
US10858638B2 (en) 2020-12-08
US20130209436A1 (en) 2013-08-15
BR112012027143B1 (pt) 2020-02-11
CA2796607A1 (en) 2011-10-27
ES2627535T3 (es) 2017-07-28
IL252115B (en) 2019-11-28
CN102985538A (zh) 2013-03-20
PL2561069T3 (pl) 2017-08-31
MX362430B (es) 2019-01-17
CA2995446C (en) 2020-05-12
LT3205351T (lt) 2023-07-25
BR112012027143A2 (pt) 2016-11-16
SI3205351T1 (sl) 2023-09-29
US20210171922A1 (en) 2021-06-10
KR101742346B1 (ko) 2017-06-15
PT2561069T (pt) 2017-05-22
EP4241854A2 (en) 2023-09-13
EP2561069B1 (en) 2017-03-08
US11560554B2 (en) 2023-01-24
IL252115A0 (en) 2017-07-31
IL222513A0 (en) 2012-12-31
JP2015204842A (ja) 2015-11-19
EP2561069A4 (en) 2014-03-26
JP6212081B2 (ja) 2017-10-11
WO2011133960A9 (en) 2013-06-13
EP3205351B1 (en) 2023-04-12
CN102985538B (zh) 2015-09-09
EP3205351A1 (en) 2017-08-16
HUE033217T2 (hu) 2017-11-28
RU2012149936A (ru) 2014-05-27
DK2561069T3 (en) 2017-05-01
EP2561069A2 (en) 2013-02-27
JP2013526856A (ja) 2013-06-27
PT3205351T (pt) 2023-06-28
HUE062163T2 (hu) 2023-09-28
ES2950358T3 (es) 2023-10-09
US20170314000A1 (en) 2017-11-02
BR112012027143A8 (pt) 2017-09-19
RU2017105260A (ru) 2018-08-17
CN105214076B (zh) 2020-03-31
CA2796607C (en) 2019-09-10
CA2995446A1 (en) 2011-10-27
AU2011242461B2 (en) 2015-10-01
HK1219655A1 (zh) 2017-04-13
PL3205351T3 (pl) 2023-08-28
JP2016190867A (ja) 2016-11-10
JP6496690B2 (ja) 2019-04-03
WO2011133960A2 (en) 2011-10-27
US10407671B2 (en) 2019-09-10
RU2017105260A3 (es) 2020-06-15
SI2561069T1 (sl) 2017-07-31
JP2018100289A (ja) 2018-06-28
KR20130113312A (ko) 2013-10-15
RU2015151189A (ru) 2019-01-14
FI3205351T3 (fi) 2023-07-06

Similar Documents

Publication Publication Date Title
MX338426B (es) Enzima de enfermedad del almacenamiento lisosomico.
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
MX2016002934A (es) Inclusion del exon 2 inducida por antisentido en la alfa-glucosidasa ácida.
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
EP2493507A4 (en) ANTAGONISTS AND VARIANTS AX213 AND AX132 PCSK9
UA109418C2 (uk) Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
MX2019009191A (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
MX2017011004A (es) Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
MY152033A (en) Anti-siglec-15 antibody
MX2012007709A (es) Variantes de alfa-amilasa con estabilidad mejorada.
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
NZ701125A (en) Improved chymosine enzyme variants
MX2013003236A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
WO2012064146A3 (ko) Ｇｋｎ １을 함유하는 항암용 조성물
MX2017001898A (es) Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
EP2414385A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF PROTEIN REGULATORY PROTEINS ON TARGET CELLS
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
MX363187B (es) Métodos y composiciones para impedir la incorrecta incorporación de norleucina en proteínas.
WO2012167133A3 (en) Inhibitors of anandamide transport and their therapeutic uses
EP2589605A4 (en) PEPTIDE INHIBITING TELOMERASE ACTIVITY, METHOD FOR PRODUCING THE SAME AND USE THEREOF
WO2011000933A3 (fr) Variants ameliores d'une phytase
WO2013063528A3 (en) Isoprene synthase variants with improved solubility for production of isoprene

Legal Events

Date Code Title Description
FG Grant or registration